{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T15:42:55Z","timestamp":1709826175278},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T00:00:00Z","timestamp":1271116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00277-010-0951-z","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T09:27:53Z","timestamp":1271064473000},"page":"109-110","source":"Crossref","is-referenced-by-count":3,"title":["Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"90","author":[{"given":"Philipp","family":"Kiewe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhard","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"951_CR1","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347\u20135356","journal-title":"J Clin Oncol"},{"key":"951_CR2","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822\u20133829","journal-title":"J Clin Oncol"},{"key":"951_CR3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","volume":"113","author":"SM Ansell","year":"2008","unstructured":"Ansell SM, Inwards DJ, Rowland KM Jr et al (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 113:508\u2013514","journal-title":"Cancer"},{"key":"951_CR4","first-page":"15s","volume":"26","author":"SM Smith","year":"2008","unstructured":"Smith SM, Pro B, Cisneros A et al (2008) Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol 26:15s, suppl; abstr 8514","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0951-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-0951-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0951-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:50:12Z","timestamp":1559037012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-0951-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-0951-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]}}}